- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02401542
Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21)
A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 1/2(b), sequential, dose escalation, open-label, randomized expansion, multicenter, efficacy and safety study of vofatamab alone or in combination with docetaxel, or versus docetaxel in FGFR3 mutant/fusion subjects with Stage IV, locally advanced or metastatic UCC who have relapsed after, or are refractory to at least one prior line of chemotherapy. Vofatamab is a novel monoclonal antibody specific for fibroblast growth factor receptor 3 (FGFR3) that is being developed to target FGFR3-positive tumors.
This study is divided into 3 phases: Phase 1b (Cohort 1), Phase 2 (Cohorts 2 and 3), and Phase 2b (Monotherapy Expansion Phase and Randomized Phase).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Olomouc, Czechia, 77900
- Research Site
-
Prague, Czechia, 12808
- Research Site
-
-
-
-
-
Ancona, Italy, 60126
- Research Site
-
Catania, Italy, 95123
- Research Site
-
Milan, Italy, 20141
- Research Site
-
Milan, Italy, 20132
- Research Site
-
Milan, Italy, 20133
- Research Site
-
Modena, Italy, 41124
- Research Site
-
Napoli, Italy, 80131
- Research Site
-
Negrar, Italy, 37024
- Research Site
-
Siena, Italy, 53100
- Research Site
-
-
-
-
-
Gwangju, Korea, Republic of, 61469
- Research Site
-
Incheon, Korea, Republic of, 405-760
- Research Site
-
Seongnam-si, Korea, Republic of, 13620
- Research Site
-
Seoul, Korea, Republic of, 03722
- Research Site
-
Seoul, Korea, Republic of, 05505
- Research Site
-
Seoul, Korea, Republic of, 03080
- Research Site
-
Seoul, Korea, Republic of, 02841
- Research Site
-
Seoul, Korea, Republic of, 06351
- Research Site
-
-
-
-
-
Badalona, Spain, 08916
- Research Site
-
Barcelona, Spain, 08036
- Research Site
-
Barcelona, Spain, 08003
- Research Site
-
Barcelona, Spain, 08026
- Research Site
-
Barcelona, Spain, 08908
- Research Site
-
Granada, Spain, 18014
- Research Site
-
Lugo, Spain, 27003
- Research Site
-
Madrid, Spain, 28046
- Research Site
-
Madrid, Spain, 28041
- Research Site
-
Madrid, Spain, 28050
- Research Site
-
Madrid, Spain, 28007
- Research Site
-
Madrid, Spain, 28033
- Research Site
-
Oviedo, Spain, 33011
- Research Site
-
Pamplona, Spain, 31008
- Research Site
-
Valencia, Spain, 46009
- Research Site
-
Vigo, Spain, 36204
- Research Site
-
-
-
-
-
Uppsala, Sweden, 751 85
- Research Site
-
-
-
-
-
Kaohsiung, Taiwan, 83301
- Research Site
-
Kaohsiung, Taiwan, 81362
- Research Site
-
Taichung, Taiwan, 40447
- Research Site
-
Taichung, Taiwan, 435
- Research Site
-
Tainan, Taiwan, 704
- Research Site
-
Taipei, Taiwan, 11217
- Research Site
-
Taipei, Taiwan, 110
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
-
-
-
Adana, Turkey, 01330
- Research Site
-
Ankara, Turkey, 06590
- Research Site
-
Antalya, Turkey, 07059
- Research Site
-
Bursa, Turkey, 16059
- Research Site
-
Edirne, Turkey, 22030
- Research Site
-
Malatya, Turkey, 44280
- Research Site
-
İstanbul, Turkey, 34732
- Research Site
-
İzmir, Turkey, 35340
- Research Site
-
-
-
-
-
London, United Kingdom, SW36JJ
- Research Site
-
Preston, United Kingdom, PR29HT
- Research Site
-
-
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Research Site
-
Goodyear, Arizona, United States, 85338
- Research Site
-
-
California
-
Duarte, California, United States, 91010
- Research Site
-
-
Florida
-
Miami, Florida, United States, 33140
- Research Site
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46845
- Reaserach Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Research Site
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Research Site
-
-
New York
-
Syracuse, New York, United States, 13210
- Research Site
-
-
Texas
-
Dallas, Texas, United States, 75390-9110
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Disease Specific Inclusion Criteria:
- Stage IV, locally advanced or metastatic (T4b, any N; or any T, N2-3) urothelial bladder cancer or TCC arising in another location of the urinary tract, including urethra, ureter, and renal pelvis
- Histological or cytological diagnosis of UCC.
- Relapsed after or are refractory to at least one prior line of chemotherapy which has not included a taxane (with the exception of Cohort 3 of Phase 2 and Phase 2b Monotherapy Expansion of Phase 2b which will allow the enrollment of patients with prior treatment with a taxane)
- Subjects must have received at least one prior chemotherapeutic regimen (at least one cycle each) for advanced or metastatic/recurrent disease, of which at least one regimen included a platinum agent (unless contraindicated).
- Prior neoadjuvant or adjuvant chemotherapy (without a taxane, except Cohort 3 of Phase 2 and Phase 2b Monotherapy Expansion, which will allow the enrollment of subjects with prior treatment with a taxane) is permitted and will not be counted as first-line chemotherapy, as long as the subject has not progressed within 12 months of the last dose.
- Measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Phase 2 and Phase 2b Specific Inclusion Criteria:
- Patient must be confirmed to have a FGFR3 genomic alteration at the time of documentation of advanced disease.
- Relapsed after or are refractory to an immune checkpoint inhibitor. This inclusion criterion does not apply if the checkpoint inhibitor is contraindicated.
Main Exclusion Criteria:
- Prior anti-cancer therapy within 2 weeks prior to Cycle 1, Day 1
- Prior treatment with an inhibitor that is targeted primarily to FGFRs
- Clinically significant comorbid medical conditions or lab abnormalities
- History of major bleeding (requiring a blood transfusion ≥ 2 units) not related to a tumor within the past 12 months
- History of clinically significant coagulation or platelet disorder in the past 12 months
- Currently receiving anticoagulation treatment
- Incomplete healing from wounds from prior surgery
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at screening
- Presence of positive test results for Hepatitis B or Hepatitis C
- Known history of human immunodeficiency virus (HIV) seropositive status
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Vofatamab plus docetaxel
IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of vofatamab, 25 mg/kg, on day one of each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1. Dosing with vofatamab and docetaxel will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor. |
Other Names:
Other Names:
|
Placebo Comparator: Placebo plus docetaxel
IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of placebo on day one of each 21-day cycle. One additional IV infusion of placebo given on Day 8 of Cycle 1. Dosing of docetaxel and placebo will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor |
Other Names:
|
Experimental: Vofatamab
IV infusion vofatamab, 25 mg/kg on day one each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1. Dosing of vofatamab will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. |
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Efficacy Outcome: Progression Free Survival (PFS)
Time Frame: 3-4 years
|
Efficacy of vofatamab plus docetaxel, compared with docetaxel plus placebo, and vofatamab alone as measured by PFS; measured from randomization to first occurrence of disease progression (per RECIST v1.1) or death, whichever occurs first.
A patient has had to receive at least one vofatamab dose.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
3-4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Rainier Therapeutics, Rainier Therapeutics
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B-701-U21
- 2017-001319-36 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Bladder Disease
-
Mansoura UniversityCompletedBladder Cancer | Bladder Disease | Bladder Neoplasm | Micro-RNAEgypt
-
TengionCompletedBladder DiseaseUnited States
-
Hospices Civils de LyonCompletedEndometrial Bladder DiseaseFrance
-
National Taiwan University HospitalCompletedRecurrence of Overactive Bladder SyndromeTaiwan
-
APOGEPHA Arzneimittel GmbHCompletedUrologic Diseases | Urinary Incontinence | Urinary Bladder, Neurogenic | Neurogenic Urinary Bladder Disorder | Bladder Disorder, Neurogenic | Urinary Bladder Disorder, Neurogenic | Neurogenic Bladder Disorder | Urinary Bladder Neurogenic Dysfunction | Overactive Detrusor FunctionRomania, Austria, Germany
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
Ankara Training and Research HospitalCompletedDisease Progression | Bladder Cancer | Recurrent Bladder Cancer
-
Mansoura UniversityActive, not recruitingBladder Cancer | Diagnoses Disease | Bladder Disease | Bladder Urothelial Carcinoma | Bladder Neoplasm | MRI Contrast Media Adverse Reaction | Bladder Cancer StageEgypt
-
Taipei Veterans General Hospital, TaiwanRecruitingOveractive Bladder SyndromeTaiwan
-
Buddhist Tzu Chi General HospitalUnknownOveractive Bladder SyndromeTaiwan
Clinical Trials on Docetaxel
-
Nereus Pharmaceuticals, Inc.CompletedCancerUnited States, Australia, India, Chile, Brazil, Argentina
-
Tianjin Medical University Cancer Institute and...Recruiting
-
Zhuhai Beihai Biotech Co., LtdCompletedSolid Tumours | Bioequivalence | DocetaxelIndia
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaCompletedNon-Small Cell Lung Cancer (NSCLC)China
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical Center and other collaboratorsUnknownGastric CancerKorea, Republic of
-
Optimal Health ResearchCompletedBreast Cancer | Lung Cancer | Prostate CancerUnited States
-
Arog Pharmaceuticals, Inc.WithdrawnCarcinoma, Non-Small-Cell Lung
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungJapan
-
SanofiCompleted
-
SanofiCompletedLung NeoplasmsFrance, Netherlands, Spain, Turkey, Belgium, Finland, Italy, United Kingdom